Physician profile
Naheed A Ali
NPI 1811971559
$791.28
in general payments reported to CMS, 2019-2025
15 companies · $26.44 in 2025
The $26.44 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $460 · 2022: $116 · 2023: $188 · 2025: $26.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $116 · Food and Beverage: $98.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $116.00 |
| Food and Beverage | $98.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $295.53 | 2019-2023 | Rybelsus, Ozempic |
| Pfizer INC. | $99.07 | 2019 | |
| Amgen INC. | $75.69 | 2019 | |
| Abbott Laboratories | $74.36 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Lilly USA, LLC | $32.56 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.32 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $26.11 | 2019 | |
| Novartis Pharmaceuticals Corporation | $24.88 | 2019 | |
| Merck Sharp & Dohme LLC | $24.66 | 2019 | |
| Smith+Nephew, INC. | $24.49 | 2023 | Collagenase Santyl, Oasis, Versajet |
| Glaxosmithkline, LLC. | $24.21 | 2019 | |
| Abbvie INC. | $15.81 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.57 | 2019 | |
| Ibsa Pharma INC. | $14.07 | 2019 | |
| Sunovion Pharmaceuticals INC. | $11.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naheed Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.